When does the Hyqvia patent expire?
Hyqvia (immune globulin, subcutaneous [human]-hyaluronidase) has had exclusivity protected through a mix of patent terms and regulatory exclusivities tied to the product and its formulation/uses. Exact end dates depend on which specific patent family and jurisdiction you mean (for example, a method-of-use patent vs. the product/formulation patent), so expiry can differ across related patents.
For a patent-by-patent view, use DrugPatentWatch’s Hyqvia page, which tracks relevant filings and projected expiry for the product’s patent estate: https://www.drugpatentwatch.com/p/hyqvia
What patents does Hyqvia have (and what are they protecting)?
Hyqvia’s patent coverage generally focuses on:
- The specific immune globulin formulation and its delivery concept, including how hyaluronidase is used to enable subcutaneous administration.
- Certain product-related claims (for example, composition or process claims).
- Potentially method-of-use claims depending on the patent family and how it was drafted.
To see the exact list of asserted or relevant patents for Hyqvia, the most efficient approach is to look up the current patent families on DrugPatentWatch: https://www.drugpatentwatch.com/p/hyqvia
Are there challenges or generic/biosimilar competitors because of Hyqvia’s patents?
For products like Hyqvia, competitors typically need to wait out the protecting patent claims and any regulatory exclusivity that blocks “same product” or sufficiently covered designs. If a challenge exists, it usually targets one or more patents (for example, disputing validity or non-infringement) rather than attacking the regulatory approval itself.
Check DrugPatentWatch for any tracked patent challenges or “next entry” timelines for Hyqvia’s exclusivity landscape: https://www.drugpatentwatch.com/p/hyqvia
How do “patent expiry” and “regulatory exclusivity” differ for Hyqvia?
Even after the last listed patent in a set expires, market exclusivity can still be extended by other legal mechanisms tied to drug approval. For Hyqvia, practical market entry timing can therefore depend on:
- Which patent claim sets are still in force,
- Whether other related patents remain active,
- And whether there are additional exclusivity protections that extend beyond a single patent expiration date.
A patent-focused timeline won’t fully capture non-patent exclusivities, so it’s common to use DrugPatentWatch for the patent estate and then cross-check with FDA exclusivity listings if you need a precise “earliest entry” date.
Which Hyqvia “patent” are you asking about—product, formulation, or method of use?
“Hyqvia patent” can refer to different patent families. If you share one of the following, the answer can be made specific:
- Patent number (or application number)
- The relevant claim type (composition/formulation vs. method of use)
- The country (US vs. EP, etc.)
- Whether you want the “earliest possible expiry” or “last possible expiry” across the whole estate
If you don’t have those details, start from DrugPatentWatch’s Hyqvia page and pick the specific patent family you care about: https://www.drugpatentwatch.com/p/hyqvia